Price
Target price
€66.06
€66.06
0.490%
0.32
0.490%
€76.30
09:31 / Tradegate
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Halozyme Therapeutics Inc. Stock
The Halozyme Therapeutics Inc. stock is trending slightly upwards today, with an increase of €0.32 (0.490%) compared to yesterday's price.
With 22 Buy predictions and 1 Sell predictions Halozyme Therapeutics Inc. is one of the favorites of our community.
With a target price of 76 € there is a slightly positive potential of 15.05% for Halozyme Therapeutics Inc. compared to the current price of 66.06 €.
Our community identified positive and negative aspects for Halozyme Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Halozyme Therapeutics Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 0.490% | -7.979% | 9.421% | 33.023% | 12.184% | 93.069% | 74.887% |
| Ligand Pharmaceuticals | 0.000% | -2.857% | 22.523% | 159.048% | 63.855% | 328.346% | 162.422% |
| United Therapeutics | 1.320% | -6.586% | -2.310% | 80.713% | 7.887% | 123.029% | 195.513% |
| Ionis Pharmaceuticals Inc. | 1.080% | -36.376% | -24.061% | 31.853% | -29.223% | 27.148% | 61.518% |
Comments
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for HALO provided by MarketBeat
News
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
Key Points
- Interested in argenex SE? Here are five stocks we like better.
- argenx said its main priorities are revenue growth, profitability and execution as it expands the VYVGART franchise
Halozyme Therapeutics Q1 Earnings Call Highlights
Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain
